Gemeinsam mit Benoit Creveau, Geschäftsführer Daiichi Sankyo Deutschland (links), Dr. Martina Witzel (2. V.l.), Leiterin des Unternehmensbereichs Onkologie, Matthias Kuehn, Werksleiter ...

See who Daiichi Sankyo Deutschland GmbH has hired for this role ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been launched in Japan for the treatment of adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) ...

TOKYO & BASKING RIDGE, N.J., March 31, 2025--(BUSINESS WIRE)--The first patient has been dosed in the DESTINY-Gastric05 phase 3 trial evaluating ENHERTU ® (trastuzumab deruxtecan) in combination ...

Daiichi Sankyo’s pexidartinib has become the first FDA-approved therapy for tenosynovial giant cell tumour (TGCT), a rare form of tumour affecting joints and tendons. TGCT – which is also ...

Just over a decade after being acquired by Daiichi Sankyo, US biotech Plexxikon will be shuttered at the end of March, with its R&D projects transferred to other areas of the Japanese group. It's ...

Ob N-TV, MDR oder Stuttgarter Zeitung: An der Magdeburger Universität soll ein „Durchbruch“ in Sachen Herstellung ...

Bengaluru/Hyderabad (Reuters) - Die derzeitige Ausnahme für die Pharmabranche von US-Zöllen stützt die Aktien des Sektors. In ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. December 24 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...